B. Riley Wealth Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-30,000
| Closed | -$66.3K | – | 1653 |
|
|
2023
Q2 | $66.3K | Hold |
30,000
| – | – | ﹤0.01% | 1467 |
|
|
2023
Q1 | $76.2K | Hold |
30,000
| – | – | ﹤0.01% | 1410 |
|
|
2022
Q4 | $56.1K | Sell |
30,000
-16,200
| -35% | -$40.4K | ﹤0.01% | 1408 |
|
|
2022
Q3 | $119K | Hold |
46,200
| – | – | ﹤0.01% | 1304 |
|
|
2022
Q2 | $90K | Hold |
46,200
| – | – | ﹤0.01% | 1137 |
|
|
2022
Q1 | $138K | Buy |
46,200
+11,500
| +33% | +$43.3K | ﹤0.01% | 1263 |
|
|
2021
Q4 | $156K | Sell |
34,700
-6,000
| -15% | -$28.5K | ﹤0.01% | 1303 |
|
|
2021
Q3 | $198K | Buy |
40,700
+12,100
| +42% | +$66.7K | 0.01% | 1249 |
|
|
2021
Q2 | $196K | Buy |
+28,600
| New | +$231K | 0.01% | 1219 |
|
|
2020
Q2 | – | Sell |
-11,800
| Closed | -$38K | – | 912 |
|
|
2020
Q1 | $38K | Sell |
11,800
-7,000
| -37% | -$25.8K | ﹤0.01% | 761 |
|
|
2019
Q4 | $76K | Buy |
18,800
+4,700
| +33% | +$16.3K | 0.01% | 803 |
|
|
2019
Q3 | $61K | Buy |
+14,100
| New | +$56.4K | 0.01% | 783 |
|
|
2019
Q2 | – | Sell |
-13,000
| Closed | -$70K | – | 842 |
|
|
2019
Q1 | $70K | Hold |
13,000
| – | – | 0.01% | 714 |
|
|
2018
Q4 | $67K | Buy |
13,000
+1,000
| +8% | +$7.59K | 0.01% | 632 |
|
|
2018
Q3 | $117K | Buy |
+12,000
| New | +$121K | 0.01% | 679 |
|
B. Riley Wealth Advisors's PRTK Position: Q3 2023 in Review
B. Riley Wealth Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 30,000 shares — an estimated $66.3K sold.
B. Riley Wealth Advisors first reported a position in PRTK in Q3 2018 and held it in 15 quarters. The position peaked at $198K in Q3 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- B. Riley Wealth Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- B. Riley Wealth Advisors sold 30,000 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $66.3K.
- B. Riley Wealth Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 15 quarters.
- B. Riley Wealth Advisors's Paratek Pharmaceuticals, Inc. position peaked at $198K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on B. Riley Wealth Advisors's 13F filing for Q3 2023, filed 1 Dec 2023.